A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate Cancer
A phase 3 trial testing BNT324 in prostate cancer, now recruiting.
Overview
A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate Cancer is a phase 3 interventional study registered as NCT07365995, led by BioNTech SE with BioNTech (Shanghai) Pharmaceuticals and DualityBio, and recruiting when checked on 2026-09-11. Official title: A Phase III, Randomised, Open-label Trial of BNT324 Versus Docetaxel With Prednisone/Prednisolone in Metastatic Castration-resistant Prostate Cancer. Planned enrolment is 736 participants (estimated). The study started in 2026-04-22 and primary completion is expected in 2031-02. No results have been posted on ClinicalTrials.gov.
Similar pages
not linked directly; found by shared links- TrialPM8002 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/Metastatic TNBC
Shares BioNTech and the tag ctgov-ingest.
- TrialPM8002 in Combination With Paclitaxel Compared With Chemotherapy as Second-line Treatment in Small Cell Lung Cancer
Shares BioNTech and the tag ctgov-ingest.
- TrialA Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1
Shares BioNTech and the tag ctgov-ingest.
- TrialSaruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents
Shares Prostate cancer and the tag ctgov-ingest.
- TrialA Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation
Shares Prostate cancer and the tag ctgov-ingest.
- TrialOpen-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy
Shares Prostate cancer and the tag ctgov-ingest.
- TrialStudy Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC
Shares Prostate cancer and the tag ctgov-ingest.
- TrialStudy of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)
Shares Prostate cancer and the tag ctgov-ingest.